ArcticZymes posts strong Q2 2026 earnings, shares rise premarket

ArcticZymes Technologies AS reported stronger-than-anticipated financial results for the second quarter of 2026, driving a 4% pre-market gain in its shares.

The Norwegian biotech company, which specializes in enzyme-based solutions for industrial and biopharmaceutical applications, posted revenue of NOK 215 million ($20.5 million) for Q2 2026, up 18% year-over-year and exceeding analyst expectations by 12%. Net profit rose to NOK 42 million, compared with a NOK 8 million loss in the same period a year earlier, as operational efficiency improved and demand for its core enzyme products strengthened.

Management attributed the outperformance to sustained growth in the biopharmaceutical sector, where ArcticZymes’ enzymes are used in drug development and manufacturing processes. The company also highlighted expansion in its industrial enzyme segment, particularly in food processing and detergent applications, as a key driver of revenue growth.

ArcticZymes’ guidance for full-year 2026 remains unchanged, with revenue projected to grow between 10% and 15% compared to 2025. The company expects continued investment in research and development to support long-term innovation, including the development of next-generation enzyme formulations for emerging applications in sustainable chemistry.

Analysts at DNB Markets noted that the results reinforce ArcticZymes’ position as a leader in niche enzyme markets, though they cautioned that macroeconomic headwinds could pressure margins in the second half of the year. Shares were trading at NOK 124.50 in pre-market activity, up from the previous close of NOK 119.70.